Pyriproxyfen for the control of Australian salt-marsh mosquito, Aedes vigilax
- Publication Type:
- Journal Article
- Citation:
- Journal of the American Mosquito Control Association, 2012, 28 (1), pp. 50 - 52
- Issue Date:
- 2012-03-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
 | 2012001410OK.pdf | 1.94 MB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
The efficacy of pyriproxyfen against the Australian salt-marsh mosquito, Aedes vigilax, was examined in 2 laboratory and 1 semi-field study using both technical grade and formulated products. In a doseresponse study, the median emergence inhibition (EI 50) and EI95 values were determined to be 0.019 and 0.076 ppb, respectively, for pyriproxyfen technical grade, 0.021 and 0.092 ppb for a microencapsulated formulation (Sumilarv® 90CS), and 0.054 and 0.236 ppb for the formulated s-methoprene product, Altosid™ Liquid Larvicide. A further laboratory comparison of the microencapsulated formulation of pyriproxyfen and Altosid, at the nominal field rate for Altosid, showed that both products provided 100% emergence inhibition and this was confirmed in a semi-field study, which also included a granular formulation of pyriproxyfen (Sumilarv 0.5G). © 2012 by The American Mosquito Control Association, Inc.
Please use this identifier to cite or link to this item: